Drugs / NP137
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06203821 | Sep 2026 → May 2027 expected | malignant pancreatic neoplasm | Aram Hezel | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05546853 | Mar 2023 → Dec 2024 | pancreatic ductal adenocarcinoma | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 1 | NCT05546879 | Mar 2023 → Mar 2026 overdue | hepatocellular carcinoma | University Hospital, Grenoble | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02977195 | Jan 2017 → Dec 2021 | endometrial carcinoma, hormone receptor-positive breast cancer | Centre Leon Berard | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06150040 | Sep 2024 → Feb 2025 | acute myeloid leukemia | Centre Leon Berard | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT04652076 | Dec 2020 → Oct 2025 overdue | cervical carcinoma, endometrial carcinoma | NETRIS Pharma | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05605496 | Jan 2023 → Jan 2027 expected | cancer, metastatic neoplasm | Centre Leon Berard | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-04-22 | NETRIS Pharma | Results NETRIS Pharma : Nature publishes positive pancreatic cancer Phase 1b data for NP137 anti-netrin-1 monoclonal antibody netrispharma.com ↗
LAPC patients treated with NP137 and mFOLFIRINOX achieved a median progression free survival (PFS) of 10.85 months, median overall survival (OS) of 16.43 months and a 23% conversion-to-surgery rate |
| 2025-10-19 | NETRIS Pharma | Results NETRIS Pharma to Present Clinical Results of NP137 in Combination with Immune Checkpoint Inhibitors at the ESMO Congress 2025 netrispharma.com ↗
NETRIS Pharma, a clinical-stage biotechnology company pioneering novel therapies targeting Netrin-1 to overcome resistance to chemotherapy and immunotherapy, today announced the presentation of the first results from its ongoing Phase 2 clinical trial IMMUNONET. |
| 2025-06-04 | NETRIS Pharma | Results Targeting NETRIN-1 in Sonic Hedgehog dependent Medulloblastoma : a Promising Therapeutic Pathway netrispharma.com ↗
Notably, the use of a NETRIN-1-blocking antibody NP137 as a single agent or in combination with SHH inhibitors results in anti-tumor activity in various animal medulloblastoma models, providing hope of new and safe therapeutic strategy for pediatric cancers. |
| 2025-04-25 | NETRIS Pharma | Results NETRIS Pharma Announces Positive Interim Phase II Results for NP137 in combination with anti-PD(L)1 netrispharma.com ↗
The interim analysis met both the primary and key secondary endpoints in secondary refractory patients. |
| 2024-11-21 | NETRIS Pharma | Regulatory NETRIS Pharma Announces FDA Orphan Drug Designation (ODD) for NP137 in Pancreatic Cancer Treatment netrispharma.com ↗
The FDA’s decision to grant ODD for NP137 highlights the critical need for innovative treatments in Pancreatic Cancer, including those designed for combination with current standards of care such as FOLFIRINOX |
| 2023-08-30 | NETRIS Pharma | Results NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology netrispharma.com ↗
Anti-netrin-1 monoclonal antibody, NP137, demonstrates objective response and disease stabilization as monotherapy in Phase 1 study of patients with advanced endometrial carcinoma (EC); effective in inhibiting tumor growth in several different preclinical mouse models. |
| 2022-03-14 | NETRIS Pharma | Results PRESS RELEASE – COMPLETION OF NP137 DOSE-ESCALATION PHASE 1 TRIAL netrispharma.com ↗
The Phase 1 dose-escalation study showed that NP137, a first-in-class monoclonal anti-netrin-1 blocking antibody, was safe and well tolerated up to 20mg/kg, with no dose limiting toxicity (DLT), meeting the primary objective. |
All press releases naming this drug 11 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NP137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06203821 ↗ |
| Action | Inhibit | “Pharmacological inhibition of netrin-1 by administration of NP137” PMID 37532929 ↗ Aug 2023 |
| Modality | Monoclonal antibody | “NP137 is a "first-in-class" humanized monoclonal antibody targeting the Netrin-1 ligand” NCT02977195 ↗ |
| Route | Intravenous | “NP137 was administrated every 2 weeks, as single agent by intravenous injection over 90 min” NCT02977195 ↗ |